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(1.9% vs. 1.5%; hazard ratio [HR]: 0.65; p ¼ 0.017) and the 2.5 mg twice-daily (1.9% vs. 1.5%; HR: 0.61; p ¼ 0.023)
treatment groups when compared with placebo, with a trend toward a reduction in the 5 mg twice-daily treatment
group (1.9% vs. 1.5%; HR: 0.70; p ¼ 0.089). Among patients who received both aspirin and a thienopyridine
(stratum 2), the beneﬁt of rivaroxaban emerged during the period of active treatment with DAPT (HR: 0.68; 95%
CI: 0.50 to 0.92, combined rivaroxaban group vs. placebo). Among stented patients who were treated with dual
antiplatelet therapy, there was a mortality reduction among those treated with twice-daily rivaroxaban 2.5 mg
(HR: 0.56; 95% CI: 0.35 to 0.89; p ¼ 0.014).Conclusions Among stented patients with ACS treated with DAPT, the administration of twice-daily rivaroxaban 2.5 mg was
associated with a reduction in stent thrombosis and mortality. (An Efﬁcacy and Safety Study for Rivaroxaban in
Patients With Acute Coronary Syndrome; NCT00809965) (J Am Coll Cardiol 2013;62:286–90) ª 2013 by the
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287The incidence of stent thrombosis is signiﬁcantly reduced
by the administration of dual antiplatelet therapy (DAPT),
implicating platelet activation as an important mediator of
this complication (3). Efforts to reduce stent thrombosis
have therefore focused on minimizing the discontinuation of
DAPT and identifying those patients who have a poor
response to thienopyridine therapy (4).
There have been relatively few contemporary studies
examining oral anticoagulation and its role in the prevention
of thrombotic complications of ACS and stent thrombosis
(3,5). Rivaroxaban is an oral anticoagulant that directly and
selectively inhibits factor Xa, interrupts the coagulation
cascade, and thereby reduces the formation of thrombin.
Inhibition of factor Xa is an attractive mechanistic target
because thrombin generated on the surface of the activated
platelet induces further platelet activation through the
thrombin receptor (protease-activated receptor 1) to form
a local positive-feedback loop (6). Indeed, rivaroxaban
successfully inhibited high-shear–induced stent thrombosis
in a porcine ex vivo model; when combined with DAPT,
rivaroxaban reduced stent thrombus weight to a nearly
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accepted March 26, 2013.was therefore hypothesized that
rivaroxaban administration is as-
sociated with a reduction in stent
thrombosis, and this hypothesis
was prospectively tested among
patients with ACS randomized
in the ATLAS-ACS 2 TIMI 51
(Anti-Xa Therapy to Lower Car-
diovascular Events in Addition
to Standard Therapy in Subjects With Acute Coronary
SyndromedThrombolysis in Myocardial Infarction 51) trial.
Methods
The ATLAS-ACS 2 TIMI 51 trial (8,9) enrolled patients
(18 years of age) who presented with symptoms suggestive
of ACS. The present analysis was restricted to patients with
a history of stent placement, including those receiving stents
before study enrollment and those who received stents
during the index PCI. Enrollment occurred within 7 days
(median: 4.3 days) of hospital admission, and patients were
randomly assigned in a 1:1:1 fashion to twice-daily admin-
istration of either 2.5 mg or 5.0 mg of rivaroxaban or
placebo, with a maximum follow-up of 31 months.
All patients were to receive standard medical therapy at the
enrolling physician’s discretion at a dose recommended in
either national or local guidelines. Stratum 1 was deﬁned as
those patients whom the enrolling physician chose to treat
with aspirin alone, and stratum 2 was deﬁned as those
patients treated with aspirin plus a thienopyridine (8,9).
The primary efﬁcacy endpoint of the ATLAS-ACS 2
TIMI 51 trial was a composite of death from cardio-
vascular causes, myocardial infarction, and stroke (ischemic,
hemorrhagic, and stroke of uncertain cause) (8). Complete
deﬁnitions of the endpoints have been reported previously (9).
Stent thrombosis was a predeﬁned endpoint reported by the
enrolling physician and was independently adjudicated based
upon the Academic Research Consortium (ARC) designa-
tions of deﬁnite, probable, or possible (2).
Statistical analysis. Efﬁcacy analyses were performed using
a modiﬁed intention-to-treat (mITT) approach, which has
been described previously (8,9). Sensitivity efﬁcacy analyses
were conducted with the use of an ITT approach, which
included all patients and all endpoint events occurring after
randomization until the global treatment end date.
Hazard ratios (HR) with 2-sided 95% conﬁdence intervals
(CI) were used to compare the study groups. Rates of the
endpoints were expressed as Kaplan-Meier estimates through
24 months. Results were examined according to major
subgroups for general consistency of treatment effect, and
interaction testing was performed.
Results
Of the 15,342 patients included in the MITT analysis,
9,631 (63%) underwent PCI and had at least 1 stent inserted
either before randomization or during their index event.
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288Aside from a slightly greater age among rivaroxaban
patients, there was no difference in baseline characteristics
between stented patients randomly assigned to rivaroxaban
versus placebo (Table 1).
ARC deﬁnite or probable (Fig. 1A) and ARC deﬁnite,
probable, or possible (Fig. 1B) stent thrombosis were signif-
icantly reduced in the pooled group of all patients treated with
rivaroxaban (both 2.5 mg and 5 mg twice-daily doses
combined). There was also a reduction in deﬁnite stent
thrombosis among all patients treated with rivaroxaban versus
placebo (Fig. 2). This reduction achieved statistical signiﬁ-
cance when limited to those patients with ARC-deﬁnedTable 1
Baseline Characteristics of the Patients Re
Stent or Index PCI Stent
Rivaroxab
Pooled (2.5 mg Tw
5 mg Twice Daily) (
Age, mean  SD, yrs 61.7  8.
Age 65 yrs, n (%) 2,292 (35.6)
Age 75 yrs, n (%) 514 (8.0)
Male, n (%) 5,081 (79.0)
CrCl, median, ml/min (IQR) 87.6 (71.2–1
Medical history
Prior MI, n (%) 1,618 (25.2)
Hypertension, n (%) 4,120 (64.0)
Diabetes, n (%) 1,991 (30.9)
Dyslipidemia, n (%) 3,287 (51.1)
Smoker, n (%) 2,776 (43.2)
Race
White, n (%) 4,867 (75.7)
Black, n (%) 45 (0.7)
Asian, n (%) 1,219 (18.9)
Other, n (%) 302 (4.7)
Weight, median, kg, (IQR) 79.2 (70.0–9
Region
North America, n (%) 496 (7.7)
South America, n (%) 699 (10.9)
Western Europe, n (%) 1,230 (19.1)
Eastern Europe, n (%) 2,086 (32.4)
Asia, n (%) 1,202 (18.7)
Other, n (%) 720 (11.2)
Index diagnosis
STEMI, n (%) 3,579 (55.6)
NSTEMI, n (%) 1,658 (25.8)
UA, n (%) 1,196 (18.6)
PCI for index event, n (%) 5,938 (92.3)
CABG for index event, n (%) 7 (0.1)
PCI or CABG for index event, n (%) 5,945 (92.4)
Medications
Aspirin, n (%) 6,311 (98.1)
Thienopyridine, n (%) 6,244 (97.1)
Beta-blocker, n (%) 4,305 (66.9)
ACEI or ARB, n (%) 2,509 (39.0)
Statin, n (%) 5,714 (88.8)
CCB, n (%) 944 (14.7)
*p Value from Wilcoxon rank sum test for continuous variables and chi-square
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor
blocker; CrCl ¼ creatinine clearance; IQR ¼ interquartile range; MI ¼ myocar
percutaneous coronary intervention; SD, standard deviation; STEMI ¼ ST-elevatideﬁnite or probable stent thrombosis in both the pooled
(HR: 0.65; p¼ 0.017) and the rivaroxaban 2.5mg twice-daily
(HR: 0.61; p ¼ 0.023) groups (Fig. 3).
The reduction in stent thrombosis with rivaroxaban
(pooled doses) was consistent across a number of subgroups
(Online Tables 1 and 2). There was homogeneity (p for
interaction ¼ 0.95) in the magnitude of the reduction in stent
thrombosis among patients in whom a bare-metal stent was
implanted (HR: 0.69; p¼ 0.042) and in whom a drug-eluting
stent was implanted (HR: 0.68; p ¼ 0.170). No signiﬁcant
reduction was noted in the small subgroup of patients who
received a stent before randomization (Online Table 3).stricted to Cohort With History of
an
ice Daily þ
n ¼ 6,433)
Placebo
(n ¼ 3,198) p Value*
9 61.1  8.9 <0.001
1,040 (32.5) 0.003
253 (7.9) 0.893
2,508 (78.4) 0.527
07.7) 88.3 (71.7–108.2) 0.388
822 (25.7) 0.557
2,026 (63.4) 0.518
976 (30.5) 0.666
1,638 (51.3) 0.915
1,396 (43.7) 0.596
0.832
2,444 (76.4)
22 (0.7)
581 (18.2)
151 (4.7)
0.0) 79.6 (69.0–90.0) 0.912
0.523
276 (8.6)
333 (10.4)
632 (19.8)
1,016 (31.8)
574 (17.9)
367 (11.5)
0.856
1,793 (56.1)
825 (25.8)
580 (18.1)
2,945 (92.1) 0.709
3 (0.1) 1.000
2,948 (92.2) 0.688
3,142 (98.3) 0.618
3,108 (97.2) 0.733
2,187 (68.4) 0.148
1,274 (39.8) 0.429
2,843 (88.9) 0.911
454 (14.2) 0.531
test or Fisher exact test for categorical variables.
blocker; CABG ¼ coronary artery bypass grafting; CCB ¼ calcium channel
dial infarction; NSTEMI ¼ non–ST-elevation myocardial infarction; PCI ¼
on myocardial infarction; UA ¼ unstable angina.
Figure 1
Kaplan-Meier Curve of Stent Thrombosis Event Rates
in the Rivaroxaban (Pooled) Group Versus Placebo
p Values presented for both intention-to-treat (ITT) and modiﬁed intention-to-treat
(mITT) analyses. (A) Deﬁnite or probable stent thrombosis event rates.
(B) Deﬁnite, probable, or possible stent thrombosis event rates. ARC ¼ Academic
Research Consortium; HR ¼ hazard ratio; KM ¼ Kaplan-Meier; Riva ¼ rivaroxaban.
Figure 2
Kaplan-Meier Rates for All ARC Deﬁnitions of Stent
Thrombosis Across Rivaroxaban Treatment Groups
*p Values presented for Rivaroxban (pooled) vs. Placebo. BID ¼ twice daily; def ¼
deﬁnite; poss ¼ possible; prob ¼ probable; other abbreviations as in Figure 1.
Figure 3
Hazard Ratios for Stent Thrombosis Endpoints Across
Rivaroxaban Treatment Groups
(A) Rivaroxaban (pooled) versus placebo. (B) Rivaroxaban 2.5 mg BID versus
placebo. (C) Rivaroxaban 5 mg BID versus placebo. CI ¼ conﬁdence interval; other
abbreviations as in Figures 1 and 2.
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effect associated with rivaroxaban administration was fairly
homogenous over time. Within 30 days of randomization,
deﬁnite, probable, or possible stent thrombosis tended to be
reduced in the pooled rivaroxaban group (HR: 0.65; 95%
CI: 0.41 to 1.03; mITT and ITT p ¼ 0.067). There was
a comparable magnitude of reduction in the HR associated
with rivaroxaban administration from 30 days to 2 years after
enrollment (HR: 0.72; 95% CI: 0.46 to 1.13; mITT
p ¼ 0.154; ITT p ¼ 0.081).
Among patients who received both aspirin and a thieno-
pyridine (stratum 2), the beneﬁt of rivaroxaban emerged
during the period of active treatment with DAPT before
any discontinuation of the thienopyridine (HR: 0.68;
95% CI: 0.50 to 0.92) in the combined rivaroxaban group
Figure 4 CV Mortality Among Stented Patients in Stratum 2
ASA ¼ aspirin (acetylsalicylic acid); CV ¼ cardiovascular; other abbreviations as in
Figures 1 and 2.
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those patients in stratum 2 treated with twice-daily rivar-
oxaban 2.5 mg (HR: 0.56; 95% CI: 0.35 to 0.89; mITT
p ¼ 0.014; ITT p ¼ 0.039) (Fig. 4) but not twice-daily
rivaroxaban 5 mg.
Discussion
Rivaroxaban administration is associated with a reduction
in stent thrombosis deﬁned using a variety of ARC deﬁ-
nitions. The beneﬁt of rivaroxaban when added to DAPT
emerged early and was preserved over time. A priori it
may have been hypothesized that rivaroxaban would
reduce the risk of stent thrombosis following cessation of
thienopyridine therapy. However, a key ﬁnding from the
present study was that rivaroxaban reduced the risk of
stent thrombosis during the period of active DAPT. It
should be noted that the oral anticoagulant apixaban
demonstrated a similar reduction in stent thrombosis in
the APPRAISE-2 (Apixaban for Prevention of Acute
Ischemic Events 2) study, but this reduction did not
reach statistical signiﬁcance because the study was stop-
ped prematurely due to an increase in major bleeding
events (10). A similar reduction in stent thrombosis was
not reported with the thrombin receptor antagonist vor-
apaxar (11).
The underlying mechanism by which rivaroxaban reduces
stent thrombosis when added to DAPT in animal and
human studies is not known. It is not known whether the
observed reduction in stent thrombosis in this study was
mediated by a reduction in thrombin generation, which in
turn directly mediates stent thrombosis, or if the reduction
in stent thrombosis was mediated by a reduction in the
stimulation of platelet aggregation because thrombin is
a potent stimulant of platelets.Conclusions
The factor Xa inhibitor rivaroxaban signiﬁcantly reduced
stent thrombosis in patients with ACS. The beneﬁt emerged
during the period of DAPT with aspirin plus a thienopyr-
idine. The results of this analysis highlight the potential
additive beneﬁt of inhibiting thrombin generation over
DAPT alone among stented patients.
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